Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Lifeloc posts 12% sales growth but pushes saliva THC device back to late 2027

The Colorado-based breath-testing firm's third-quarter sales rose and its loss shrank, yet its first drug-testing product now depends on funding and is nine months later than planned.

16 Nov 2026 · Lifeloc Technologies, Inc LCTC · Company news

Lifeloc Technologies recorded revenue of $2.522 million for the three months to 30 September 2026, 12% more than in the same quarter of 2025. Gross margin came to 43%, and the bottom line showed a loss of $85,000, smaller than before.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Lifeloc Technologies, Inc ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →